See the DrugPatentWatch profile for polivy

Polivy, also known as polatuzumab vedotin-piiq, is a medication used to treat certain types of non-Hodgkin's lymphoma, a type of blood cancer. According to the drug's prescribing information, the most common side effects of Polivy include:

1. Decreased white blood cell count (neutropenia) [1]
2. Decreased red blood cell count (anemia) [1]
3. Decreased platelet count (thrombocytopenia) [1]
4. Fatigue [1]
5. Diarrhea [1]
6. Pyrexia (fever) [1]
7. Nausea [1]
8. Upper respiratory tract infection [1]
9. Peripheral neuropathy (nerve damage) [1]
10. Decreased appetite [1]

It is important to note that these side effects may not occur in all patients and some may be more severe than others. Patients should consult with their healthcare provider for a full list of potential side effects and to discuss any concerns they may have.

Sources:

[1] Polivy (polatuzumab vedotin-piiq) injection, for intravenous use, prescribing information. Genentech, Inc. [Online] 2021. [Cited: February 21, 2023.] <https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761146s000lbl.pdf>